Trial reportLasers in medical science2020
Clinical outcomes of micropulse transscleral cyclophotocoagulation in refractory glaucoma-18 months follow-up.
Trial report in Lasers in medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- The efficacy and safety of micropulse transscleral laser treatment in glaucoma: a systematic review and meta-analysis.BMC ophthalmology · 2023Pooled it
- Outcomes of Micropulse Transscleral Cyclophotocoagulation in Primary Open-Angle and Pseudoexfoliative Glaucoma.Medicina (Kaunas, Lithuania) · 2026Article
- Intraocular pressure changes and pain scores within 24 hours and short-term outcomes after micropulse transscleral laser therapy.PloS one · 2026Article
- Outcomes of micropulse transscleral cyclophotocoagulation using different sweep velocity in the treatment of refractory glaucoma.Scientific reports · 2025Article
- In vivo confocal microscopy (IVCM) analysis of corneal sub-basal nerve plexus (SNP) and corneal sensitivity after micropulse transscleral cyclophotocoagulation (MP-TSCPC) in glaucoma patients.International ophthalmology · 2025Article
- Micropulse Cyclophotocoagulation versus Ultrasound Cycloplasty in a Tertiary Eye Care Center in Riyadh, Saudi Arabia.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Comparison of Efficacy of Micropulse Laser Settings for Glaucoma Management.Journal of clinical medicine · 2024Article
- The effect of cumulative energy in repeated subliminal transscleral cyclophotocoagulation: a retrospective study.BMC ophthalmology · 2024Article
- Micropulse transscleral laser therapy for secondary angle-closure glaucoma in nanophthalmos: a case report.International journal of ophthalmology · 2024Article
- Micropulse Transscleral Cyclophotocoagulation in Non-Incisional Eyes with Ocular Hypertension and Primary Open-Angle Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Micropulse Transscleral Cyclophotocoagulation Results in Secondary Glaucoma.Life (Basel, Switzerland) · 2023Article
- Assessment of Pain in Glaucoma Patients Undergoing Micropulse Transscleral Laser Therapy.Journal of clinical medicine · 2023Article
- Evidence-Based Consensus Guidelines Series for MicroPulse Transscleral Laser Therapy - Surgical Technique, Post-Operative Care, Expected Outcomes and Retreatment/Enhancements.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Efficacy and safety of ultrasound cycloplasty for the treatment of glaucoma: a Meta-analysis.International journal of ophthalmology · 2023Article
- Phacoemulsification combined with micropulse cyclodiode laser in glaucoma patients: efficacy and safety.Eye (London, England) · 2022Article
- Micropulse Transscleral Cyclophotocoagulation for Glaucoma after Penetrating Keratoplasty.Diagnostics (Basel, Switzerland) · 2022Article
- Micropulse vs. continuous wave transscleral cyclophotocoagulation in neovascular glaucoma.Experimental and therapeutic medicine · 2022Article
- Micropulse Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma in Taiwan during the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2021Article
- Comparative efficacy and safety of micropulse transscleral laser cyclophotocoagulation using different duration protocols in eyes with good visual acuity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers.Experimental and therapeutic medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to evaluate the clinical outcomes of micropulse transscleral cyclophotocoagulation (mTSCPC) in cases of refractory glaucoma. Patients with refractory glaucoma were selected to undergo mTSCPC, using the MP3 handpiece from Iridex Laser Systems. Follow-up examinations occurred on a regular basis for 18 months after the procedure. One hundred eyes of 97 patients were treated. Mean pre-laser intraocular pressure (IOP) was 39.14 ± 13.84 mmHg. This was reduced significantly to 22.77.8 ± 10.48 mmHg (41.82% reduction; p < 0.001) at week 1. At months 1, 3, 6, 12, and 18 the IOP mean was 23.81 ± 9.44, 24.27 ± 9.17, 23.09 ± 8.47, 22.76 ± 8.14, and 22.77 ± 8.13 mmHg. The success rate at 18 months was the highest 90.91% for the group with IOP below 26 mmHg and the lowest 70.00% for the IOP group 26-30 mmHg. The mean number of anti-glaucoma drops decreased from 2.63 ± 0.87 to 1.78 ± 0.95. The number of treatments performed was 1.26. The pain felt during the procedure was reported as being moderate. No major postoperative complications were noted. Micropulse transscleral cyclophotocoagulation is a non-invasive, repeatable laser procedure that offers both good and stable results in lowering IOP and decreases the use of antiglaucoma medications for up to 18 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.